Community Code Relating to Medicinal Products for Human Use
The consolidated EU code for human medicines: the marketing-authorisation requirement and its dossier, manufacturing and wholesale-distribution authorisations, labelling and package-leaflet requirements, advertising rules, and the pharmacovigilance obligations of the authorisation holder.
What this does not cover
stated in the document's own scope- Veterinary medicines are outside it. The Directive applies to medicinal products for human use only.
- Centrally authorised products follow Regulation (EC) No 726/2004 for their authorisation procedure, although much of the Directive — manufacturing, labelling, distribution — still applies to them.
- Clinical trials are regulated separately; Article 3 excludes products intended for research and development trials from the Directive, without prejudice to the clinical-trials legislation.
- Title IV is the exception to the finished-product focus: under Article 2(3) it also applies to products made only for export, intermediates, active substances and excipients.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Directive 2001/83/EC is the Community code relating to medicinal products for human use — the consolidated EU law that decides when a human medicine may be placed on the market and what must be true of the companies that make, distribute, label and promote it. It applies to medicinal products intended to be placed on the market in Member States and prepared industrially or by an industrial process. Within one text it covers the marketing-authorisation dossier, the manufacturing authorisation and the Qualified Person, labelling and package leaflets, legal classification for supply, wholesale distribution and brokering, advertising, and the pharmacovigilance obligations of the authorisation holder.
Scope & applicability
Human medicinal products placed on the EU market through national, mutual-recognition and decentralised routes; the centralised procedure is governed by Regulation (EC) No 726/2004 alongside it. As a Directive it binds through national transposition, so the operative text a company complies with is its Member State law.
Legal basis & how it acquires force
It is a Directive of the European Parliament and of the Council, dated 6 November 2001 and published in OJ L 311 of 28 November 2001. As a Directive it binds Member States as to the result and is given effect through national law, so the text a company complies with day to day is its Member State’s transposition. It has been amended many times, including by Directive 2010/84/EU on pharmacovigilance, Directive 2011/62/EU on falsified medicines and Directive (EU) 2022/642; EUR-Lex publishes consolidated versions, the most recent dated 1 January 2025. Consolidated text is a documentation tool only; the Official Journal text is authentic.
Document structure
| Part | Covers |
|---|---|
| Titles I–II — Definitions and scope | What counts as a medicinal product and the exclusions in Article 3, such as magistral and officinal formulae and products for research and development trials |
| Title III — Placing on the market | Article 6, under which no medicinal product may be placed on the market without an authorisation, and the application dossier submitted in accordance with Annex I |
| Title IV — Manufacture and importation | The manufacturing authorisation (Article 40), the holder’s obligations (Article 46) and the Qualified Person (Articles 48 to 51) |
| Titles V–VI — Labelling, package leaflet and classification | Particulars for outer and immediate packaging (from Article 54) and classification as prescription or non-prescription (Article 70) |
| Titles VII–VIIIa — Distribution, brokering, advertising and information | The wholesale-distribution authorisation (Article 77) and the advertising rules, including Article 87’s requirement that advertising comply with the summary of product characteristics |
| Titles IX–XIV — Pharmacovigilance, blood products, supervision and final provisions | The pharmacovigilance systems of Member States and authorisation holders (Articles 101 and 104), plasma-derived products, inspection and sanctions |
Key requirements
- Article 6 — no medicinal product may be placed on the market without an authorisation
- Article 40 — manufacture requires a manufacturing authorisation; Article 46 sets the holder’s obligations, including the Qualified Person
- Title V — labelling and package leaflet, including the readability and language requirements
- Title VII — wholesale distribution and brokering; Titles VIII and VIIIa — advertising and information, where Article 87 requires all advertising to comply with the particulars of the summary of product characteristics
Implementation tips
- Read it as transposed: the Directive sets the requirement, national law sets the text an inspector cites, and the two can differ in detail
- The 2026 EU pharmaceutical package would replace this Directive and Regulation (EC) No 726/2004. The Council adopted its first-reading position on 28 September 2026 and, as of October 2026, the package awaits the European Parliament’s second-reading vote, so 2001/83/EC as amended remains the instrument in force — plan against it, and watch the package rather than citing it
Revision notes
Amended many times since 2001, notably by Directive 2010/84/EU (pharmacovigilance) and Directive 2011/62/EU (falsified medicines). A full replacement is proposed under the 2026 EU pharmaceutical package: trilogue concluded December 2025, compromise texts published by the Council March 2026, Council first-reading position adopted 28 September 2026; awaiting the European Parliament’s second reading as of October 2026.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The Directive works alongside Regulation (EC) No 726/2004, which governs the centralised authorisation procedure; Article 6 recognises authorisation under either. Its Article 47 empowers the Commission to set the principles and guidelines of good manufacturing practice by delegated act, provides for detailed guidelines in line with those principles, and requires guidelines on good distribution practice for active substances — the legal anchor for the EU GMP Guide and the active-substance GDP guidelines. Article 51 ties the Qualified Person’s batch certification to both the law and the marketing authorisation.
Directive 2001/83/EC: frequently asked questions
Quick answers to common questions about Directive 2001/83/EC.
Is Directive 2001/83/EC directly binding on companies?
Not as such. A Directive is addressed to Member States and takes effect through national transposing law, so a company’s legal obligations arise under its Member State’s legislation implementing the Directive. Regulations, such as Regulation (EC) No 726/2004, apply directly.
Where does the Qualified Person come from?
From Title IV. Article 48 requires the manufacturing-authorisation holder to have at least one qualified person permanently and continuously at its disposal, Article 49 sets the qualifications, and Article 51 makes the QP responsible for confirming that each batch was manufactured and checked in accordance with the law and the marketing authorisation.
Which parts of the Directive cover distribution?
Title VII covers wholesale distribution and brokering. Article 77 requires an authorisation to act as a wholesaler, stating the premises for which it is valid, and later articles set the obligations of wholesalers and brokers, including for supplies to third countries.
What did the 2011 amendment add?
Directive 2011/62/EU, the falsified-medicines amendment, brought brokering into Title VII, applied Title IV to active substances and excipients through Article 2(3), introduced safety features for prescription medicines (Article 54a) and set rules for offering medicines for sale at a distance (Article 85c), among other changes.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.